Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.37 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260349 | 0.98 | ZDHHC7 (0.44) | ZDHHC7GPR84FFAR1CPB2MAPT | |
| SCHEMBL2803737 | 0.98 | ZDHHC7 (0.44) | ZDHHC7GPR84FFAR1CPB2MAPT | |
| Acetic Acid SCHEMBL9301447 | 0.93 | GPR84 (0.42) | ZDHHC7GPR84FFAR1CPB2MAPT | |
| SCHEMBL13269368 | 0.88 | ZDHHC7 (0.47) | ZDHHC7GPR84CA1FFAR1CPB2 | |
| SCHEMBL6772533 | 0.86 | GPR84 (0.42) | ZDHHC7GPR84FFAR1CPB2MAPT | |
| SCHEMBL7070785 | 0.86 | ZDHHC7 (0.50) | ZDHHC7GPR84FFAR1CPB2MAPT | |
| SCHEMBL19690704 | 0.86 | ZDHHC7 (0.50) | ZDHHC7GPR84FFAR1CPB2MAPT | |
| SCHEMBL3682993 | 0.82 | CA1 (0.44) | ZDHHC7GPR84CA1FFAR1CPB2 | |
| SCHEMBL234311 | 0.81 | CA2 (0.47) | ZDHHC7CA1CPB2CA2 | |
| SCHEMBL17713606 | 0.81 | ZDHHC7 (0.46) | ZDHHC7GPR84CA1FFAR1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10150752-B2 | Substituted triazole derivatives as oxytocin antagonists | IXCHELSIS LIMITED (GB) | 2018-12-11 | — | — | US | disclosed |
| US-20170114040-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2017-04-27 | — | — | US | disclosed |
| US-9394278-B2 | Substituted triazole derivatives as oxytocin antagonists | IXCHELSIS LIMITED (GB) | 2016-07-19 | — | — | US | disclosed |
| US-20150322042-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2015-11-12 | — | — | US | disclosed |
| US-9023872-B2 | Substituted triazole derivatives as oxytocin antagonists | IXCHELSIS LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| US-20130137671-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | PFIZER INC. | 2013-05-30 | — | — | US | disclosed |
| US-8207198-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-1841758-B1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2009-11-18 | — | — | EP | disclosed |
| US-20090253674-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-7557131-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1841758-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | Pfizer Limited (GB) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006077496-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160786-A1 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC | 2006-07-20 | — | — | US | disclosed |
| EP-0962457-B1 | Piperidones as tachykinin antagonists | PFIZER LTD (GB) | 2003-08-06 | — | — | EP | disclosed |
| US-20010044445-A1 | AZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES | 2001-11-22 | — | — | US | disclosed |
| EP-1068187-A1 | PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-0962457-A1 | Piperidones as tachykinin antagonists | Pfizer Limited (GB) | 1999-12-08 | — | — | EP | disclosed |
| WO-1999051580-A1 | PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137671-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | OXTR, AVPR1B, GNRHR | ZDHHC7 2499/4885GPR84 505/4885CA1 4194/4885 |
| US-20170114040-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | OXTR, AVPR1B, GNRHR | ZDHHC7 2499/4885GPR84 505/4885CA1 4194/4885 |
| US-20150322042-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | OXTR, AVPR1B, GNRHR | ZDHHC7 2499/4885GPR84 505/4885CA1 4194/4885 |
| US-20060160786-A1 | Substituted triazole derivatives as oxytocin antagonists | OXTR, AVPR1B, GNRHR | ZDHHC7 2499/4885GPR84 505/4885CA1 4194/4885 |
| US-20090253674-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | OXTR, AVPR1B, GNRHR | ZDHHC7 2499/4885GPR84 505/4885CA1 4194/4885 |
| US-10150752-B2 | Substituted triazole derivatives as oxytocin antagonists | OXTR, AVPR1B, GNRHR | ZDHHC7 2499/4885GPR84 505/4885CA1 4194/4885 |
| US-20010044445-A1 | AZOLE INHIBITORS OF CYTOKINE PRODUCTION | IL5, IL2, IL4 | ZDHHC7 1587/4885GPR84 1513/4885CA1 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.